# Distillation Samples Comparison: MedGemma vs GPT-OSS

This document compares MedGemma and GPT-OSS distillation sample outputs and preserves the full sample text for both.

## MedGemma Run (Full Samples)

Source: `distillation/examples/distillation_examples_medgemma.md`

# Distillation Output Examples (MedGemma)

One representative MedGemma distilled sample per dataset (from the 2-example distillation test output).

| dataset | source_rows | sampled_rows | distilled_rows | sample_coverage | empty_answer_rate | notes |
|---|---:|---:|---:|---:|---:|---|
| afrimedqa_v1_test_3000_with_labels.jsonl | 3000 | 2 | 2 | 100.00% | 0.00% | - |
| afrimedqa_v2_full_15275_with_labels.jsonl | 15275 | 2 | 2 | 100.00% | 0.00% | - |
| healthsearchqa_3375_no_labels.jsonl | 3375 | 2 | 2 | 100.00% | 0.00% | - |
| liveqa_truehealth_635_with_labels.jsonl | 635 | 2 | 2 | 100.00% | 0.00% | - |
| medexpqa_train_434.jsonl | 434 | 2 | 2 | 100.00% | 0.00% | - |
| medmcqa_with_labels.jsonl | 182822 | 2 | 2 | 100.00% | 0.00% | - |
| medqa_with_labels_5opt.jsonl | 10178 | 2 | 2 | 100.00% | 0.00% | - |
| pubmedqa_pqa_labeled_1000_medgemma_style_with_labels.jsonl | 1000 | 2 | 2 | 100.00% | 0.00% | - |

## Examples

### afrimedqa_v1_test_3000_with_labels.jsonl

- id: `265049d633cd0f3229d266a5284aa104eba52196034cb16afe7a0a70bac253f6`
- true_label: `option4`
- source_row_index: `0`
- question_preview: Question: A 34-year-old man presents with a 1-week history of muscle aches, fatigue, and fever that occurs every 2 days. His history is significant for a trip to Nepal. Vital signs...
- distilled_model: `google/medgemma-27b-text-it`
- distilled_timestamp_utc: `2026-02-27T19:18:42.214077+00:00`

#### Source answer(s)

- true_label: `option4`
- true_rationale:

> A patient with recent travel history, cyclical fever, and brick red granules (Schüffner stippling) in erythrocytes suggests the diagnosis of malaria. The patient was most likely treated with chloroquine, a quinoline derivative that is a first-line agent for Plasmodium vivax and P. ovale infections. Chloroquine can cause marked QT prolongation and can cause severe ventricular arrhythmias like torsades de pointes.
> 
> Patients on antimalarials should be monitored with an ECG regularly. The common side effect of chloroquine is gastrointestinal upset (GI), headache, blurred vision, and insomnia.
> 
> Doxycycline and tetracycline are usually well-tolerated, but some GI upset can be seen and, less commonly, ultraviolet photosensitivity
> 
> Metronidazole and pyrimethamine drugs are not effective against malaria.

- source_assistant_answer:

> Correct answer: option4
> Explanation: A patient with recent travel history, cyclical fever, and brick red granules (Schüffner stippling) in erythrocytes suggests the diagnosis of malaria. The patient was most likely treated with chloroquine, a quinoline derivative that is a first-line agent for Plasmodium vivax and P. ovale infections. Chloroquine can cause marked QT prolongation and can cause severe ventricular arrhythmias like torsades de pointes.
> 
> Patients on antimalarials should be monitored with an ECG regularly. The common side effect of chloroquine is gastrointestinal upset (GI), headache, blurred vision, and insomnia.
> 
> Doxycycline and tetracycline are usually well-tolerated, but some GI upset can be seen and, less commonly, ultraviolet photosensitivity
> 
> Metronidazole and pyrimethamine drugs are not effective against malaria.

#### Distilled answer

<unused94>thought
The patient presents with symptoms suggestive of malaria, including fever, muscle aches, fatigue, and a history of travel to Nepal, an endemic area. The physical examination findings of icterus and splenomegaly further support this diagnosis. The laboratory results show anemia (hemoglobin 11 g/dL) and the peripheral smear reveals erythrocytes with brick-red granules, which are characteristic of Plasmodium falciparum infection (Schüffner's dots are seen in P. vivax and P. ovale, while Maurer's clefts are seen in P. falciparum, but brick-red granules are not a typical description for any specific Plasmodium species, though they might refer to the appearance of infected RBCs or other findings. However, the overall clinical picture strongly points towards malaria, likely P. falciparum given the severity and potential complications).

The patient is hospitalized and started on appropriate therapy. On the 3rd hospital day, he develops a sudden increase in heart rate, and an ECG is obtained. The ECG shows a prolonged QT interval. We need to identify the most likely drug administered that could cause QT prolongation.

Let's evaluate the options:

1.  **Metronidazole:** Used for anaerobic infections and certain protozoal infections (e.g., Giardia, Trichomonas). It is not a standard treatment for malaria. While it can have side effects, significant QT prolongation is not a common or characteristic adverse effect.
2.  **Pyrimethamine:** An antifolate drug used in combination with sulfadoxine (Fansidar) for malaria treatment or prophylaxis, and also for toxoplasmosis. It is not typically used as monotherapy for malaria. QT prolongation is not a well-known side effect.
3.  **Ciprofloxacin:** A fluoroquinolone antibiotic. It is not used for malaria treatment. Fluoroquinolones are known to cause QT prolongation, but it's not the drug used for malaria.
4.  **Chloroquine:** An antimalarial drug, historically used for P. falciparum, but resistance is widespread. It is still used for P. vivax, P. ovale, and P. malariae. Chloroquine is well-known to cause QT prolongation and cardiac arrhythmias, especially in patients with pre-existing heart conditions or when administered intravenously rapidly. Given the patient's presentation suggestive of malaria and the development of tachycardia and ECG changes (QT prolongation), chloroquine is a plausible drug that could have been administered, especially if the specific Plasmodium species was not immediately identified or if it was a P. vivax/ovale/malariae case. However, P. falciparum is more likely given the severity and potential complications, and chloroquine is often not the first-line treatment for severe falciparum malaria due to resistance.
5.  **Doxycycline:** A tetracycline antibiotic also used for malaria prophylaxis and treatment (often in combination with other drugs like quinine or artesunate). While tetracyclines can have various side effects, significant QT prolongation is not a commonly reported or major adverse effect associated with doxycycline.

Considering the clinical scenario (suspected malaria, likely P. falciparum given severity, potential complications like icterus and splenomegaly) and the adverse effect (tachycardia and QT prolongation on ECG), we need to choose the most likely antimalarial drug among the options that is known to cause QT prolongation.

Chloroquine is a well-established antimalarial drug known to cause QT prolongation and cardiac toxicity. Although resistance limits its use for P. falciparum in many areas, it might still be used for other Plasmodium species or in specific situations. The ECG finding of QT prolongation strongly points towards chloroquine as a potential causative agent among the listed antimalarials.

Other antimalarials commonly used for P. falciparum, such as quinine, artemisinins, mefloquine, and atovaquone/proguanil, also have potential cardiac side effects, but chloroquine is particularly noted for QT prolongation. Quinine can also cause QT prolongation and cinchonism. Mefloquine can cause neuropsychiatric effects and rarely QT prolongation. Artemisinins are generally well-tolerated regarding cardiac effects. Atovaquone/proguanil is generally considered safe regarding QT interval.

Given the options provided, chloroquine is the most likely drug to cause QT prolongation. The patient's symptoms (fever, myalgia, fatigue, icterus, splenomegaly) and travel history strongly suggest malaria. The development of tachycardia and ECG showing QT prolongation points to a drug side effect. Among the listed drugs used for malaria or related conditions, chloroquine is the most notorious for causing QT prolongation.<unused95>Rationale Breakdown:
1.  **Clinical Presentation:** The patient presents with symptoms highly suggestive of malaria (fever, myalgia, fatigue, icterus, splenomegaly) after traveling to Nepal, an endemic area. The peripheral smear finding of erythrocytes with

### afrimedqa_v2_full_15275_with_labels.jsonl

- id: `ff784abc6b461a6a15d7f8bf5e6560d3393474fe4748699ff4c7f2124292b95f`
- true_label: `None`
- source_row_index: `0`
- question_preview: Prompt: Your female friend complains of weight gain, high blood pressure and thinks she has Lupus Nephritis and is going to visit the nearest doctor. Question: Question: Can you pr...
- distilled_model: `google/medgemma-27b-text-it`
- distilled_timestamp_utc: `2026-02-27T19:18:42.214096+00:00`

#### Source answer(s)

- true_label: `None`
_(no source assistant answer found for this sample)_

#### Distilled answer

<unused94>thought
Here's a thinking process for generating the response about stress management and mental well-being for someone concerned about potential Lupus Nephritis:

1.  **Understand the User's Need:** The user's friend is experiencing symptoms (weight gain, high blood pressure) and is worried about a specific serious condition (Lupus Nephritis). She's seeking advice on stress management and mental well-being *in relation to this situation*. This means the advice needs to be sensitive to the anxiety and uncertainty she's likely feeling.

2.  **Acknowledge and Validate:** Start by acknowledging the friend's feelings. It's crucial to validate her concerns without confirming or denying the diagnosis (as that's the doctor's job). Phrases like "It's completely understandable to feel stressed and anxious" or "Dealing with potential health concerns is incredibly challenging" are good starting points.

3.  **Emphasize the Importance of Medical Consultation:** This is paramount. The friend is *already* planning to see a doctor, which is excellent. Reinforce this. Stress management is *supportive*, not a *replacement* for medical diagnosis and treatment. State clearly that a doctor is the only one who can diagnose and provide appropriate medical care.

4.  **Brainstorm Stress Management Techniques:** Think broadly about common and effective stress reduction methods. Categorize them for clarity.
    *   **Mindfulness/Relaxation:** Deep breathing, meditation, yoga, progressive muscle relaxation.
    *   **Physical Activity:** Exercise (gentle, as appropriate), walking, stretching.
    *   **Social Support:** Talking to trusted friends/family, support groups.
    *   **Cognitive/Behavioral:** Journaling, challenging negative thoughts, setting realistic expectations, limiting exposure to overwhelming information.
    *   **Lifestyle:** Healthy diet (relevant to weight gain/BP), adequate sleep, limiting caffeine/alcohol.
    *   **Professional Help:** Therapy, counseling.

5.  **Tailor Techniques to the Specific Situation:** How do these general techniques apply to someone worried about a serious illness like Lupus Nephritis?
    *   **Information Management:** The internet can be overwhelming and scary. Advise seeking reliable sources (doctor, reputable health organizations) and limiting "Dr. Google."
    *   **Focus on Control:** Acknowledge that she can't control the diagnosis, but she *can* control her actions (seeing the doctor, managing stress, healthy habits).
    *   **Patience:** Diagnosis and treatment take time. Encourage patience with the process.
    *   **Self-Compassion:** It's okay to feel scared, overwhelmed, or sad. Encourage kindness towards herself.
    *   **Preparation for Doctor's Visit:** Suggest writing down symptoms, questions, and concerns to make the appointment more productive and less anxiety-provoking.

6.  **Structure the Response:** Organize the points logically.
    *   **Opening:** Acknowledge feelings, emphasize seeing the doctor.
    *   **Stress Management Strategies (Categorized):**
        *   Mindfulness & Relaxation
        *   Physical Activity (with a caveat about consulting the doctor)
        *   Social Support
        *   Information Management & Cognitive Strategies
        *   Lifestyle Adjustments (Diet, Sleep)
        *   Professional Support
    *   **Specific Tips for the Situation:** Focus on control, patience, self-compassion, preparing for the doctor.
    *   **Closing:** Reiterate support, encourage seeking professional help (both medical and mental health), and offer continued friendship.

7.  **Refine Language:** Use empathetic and supportive language. Avoid medical jargon. Be encouraging but realistic. Ensure the tone is helpful and non-judgmental. Add disclaimers (e.g., "I am not a medical professional").

8.  **Self-Correction/Review:**
    *   Did I directly answer the question about stress management and mental well-being *in relation to her condition*? Yes.
    *   Did I emphasize the importance of seeing a doctor? Yes, multiple times.
    *   Is the advice practical and actionable? Yes.
    *   Is the tone appropriate? Yes, empathetic and supportive.
    *   Did I avoid giving medical advice or diagnosis? Yes.
    *   Is it clear that these are *supportive* measures, not cures? Yes.
    *   Could I add anything else? Maybe a specific mention of support groups for autoimmune conditions or chronic illness, if appropriate. (Added this).

This thought process leads to a comprehensive, empathetic, and responsible response that addresses the user's request while prioritizing the friend's need for professional medical evaluation.<unused95>Okay, it's completely understandable that your friend is feeling stressed and anxious given her symptoms and concerns about Lupus Nephritis. Dealing with potential health issues is

### healthsearchqa_3375_no_labels.jsonl

- id: `1`
- true_label: `None`
- source_row_index: `0`
- question_preview: Are benign brain tumors serious?
- distilled_model: `google/medgemma-27b-text-it`
- distilled_timestamp_utc: `2026-02-27T19:18:42.214103+00:00`

#### Source answer(s)

- true_label: `None`
_(no source assistant answer found for this sample)_

#### Distilled answer

Yes, benign brain tumors can be serious, even though they are not cancerous. Here's a breakdown of why:

**Why they can be serious:**

1.  **Location, Location, Location:** The brain is a confined space (the skull). Even a slow-growing, non-cancerous tumor can press on, displace, or damage critical brain structures like nerves, blood vessels, or specific brain regions responsible for functions like movement, speech, vision, or cognition.
2.  **Increased Intracranial Pressure (ICP):** As a tumor grows, it takes up space within the skull. This can increase pressure inside the skull, leading to symptoms like headaches, nausea, vomiting, vision changes, and drowsiness. Severe ICP can be life-threatening.
3.  **Functional Impairment:** Depending on where the tumor is located, it can interfere with normal brain function, causing a wide range of symptoms:
    *   **Motor problems:** Weakness, clumsiness, balance issues, seizures.
    *   **Sensory changes:** Numbness, tingling, vision or hearing loss.
    *   **Cognitive issues:** Memory problems, difficulty concentrating, personality changes.
    *   **Speech difficulties:** Trouble finding words or speaking clearly.
    *   **Hormonal imbalances:** If the tumor affects the pituitary gland or hypothalamus.
4.  **Potential for Growth:** While benign tumors don't spread (metastasize) like cancerous ones, they can still grow over time. Some may grow very slowly, while others can grow more rapidly, requiring intervention.
5.  **Surgical Risks:** Removing a brain tumor, even a benign one, is a complex neurosurgical procedure. The surgery itself carries risks, including bleeding, infection, damage to surrounding brain tissue, and potential long-term neurological deficits. The location of the tumor significantly impacts the difficulty and risk of surgery.
6.  **Recurrence:** Even after successful removal, some benign tumors can recur (grow back).

**Key Differences from Malignant (Cancerous) Brain Tumors:**

*   **Growth Rate:** Benign tumors typically grow more slowly than malignant tumors.
*   **Spread:** Benign tumors do not invade nearby tissues aggressively or spread to other parts of the body (metastasize). Malignant tumors do.
*   **Cell Appearance:** Under a microscope, benign tumor cells look more like normal brain cells, while malignant tumor cells look abnormal.
*   **Prognosis:** Generally, the prognosis for benign brain tumors is better than for malignant ones, especially if they can be completely removed. However, this depends heavily on location, size, and the patient's overall health.

**In summary:**

While the term "benign" means non-cancerous, it doesn't mean "harmless" when it comes to brain tumors. Their potential to cause significant neurological problems due to pressure and location makes them a serious medical condition that often requires careful monitoring and treatment, which may include surgery, radiation, or medication.

If you or someone you know has been diagnosed with a brain tumor, it's crucial to discuss the specific type, location, size, and treatment options with a medical team, particularly a neurosurgeon and neurologist.

### liveqa_truehealth_635_with_labels.jsonl

- id: `1`
- true_label: `Cardiac amyloidosis is a disorder caused by deposits of an abnormal protein (amyloid) in the heart tissue. These deposits make it hard for the heart to work properly.`
- source_row_index: `0`
- question_preview: Literature on Cardiac amyloidosis. Please let me know where I can get literature on Cardiac amyloidosis. My uncle died yesterday from this disorder. Since this is such a rare disor...
- distilled_model: `google/medgemma-27b-text-it`
- distilled_timestamp_utc: `2026-02-27T19:18:42.214109+00:00`

#### Source answer(s)

- true_label: `Cardiac amyloidosis is a disorder caused by deposits of an abnormal protein (amyloid) in the heart tissue. These deposits make it hard for the heart to work properly.`
- source_assistant_answer:

> Cardiac amyloidosis is a disorder caused by deposits of an abnormal protein (amyloid) in the heart tissue. These deposits make it hard for the heart to work properly.

#### Distilled answer

I am so sorry to hear about the loss of your uncle. It's a thoughtful gesture to want to share information about cardiac amyloidosis at his service to honor his memory and raise awareness.

Given your background and location, here are several resources and suggestions for obtaining literature on cardiac amyloidosis, including options at NIH:

**1. National Heart, Lung, and Blood Institute (NHLBI) - Part of NIH:**

*   **Website:** The NHLBI website has extensive information on various heart conditions, including amyloidosis. Search for "cardiac amyloidosis" on their site ([https://www.nhlbi.nih.gov/](https://www.nhlbi.nih.gov/)). They often have fact sheets, summaries, and links to research.
*   **Contact:** You could try contacting the NHLBI Health Information Center directly. As a former NIH employee, you might have contacts or know the best way to reach them. They may be able to provide printed materials or direct you to relevant resources.
*   **Location:** The NHLBI is located on the NIH campus in Bethesda, Maryland.

**2. National Institute on Aging (NIA) - Part of NIH:**

*   **Website:** Amyloidosis, particularly AL amyloidosis, can affect older adults. The NIA website ([https://www.nia.nih.gov/](https://www.nia.nih.gov/)) might have relevant information, especially regarding diagnosis and treatment in the elderly.
*   **Contact:** Similar to NHLBI, contacting their health information resources might yield helpful materials.

**3. Amyloidosis Foundation:**

*   **Website:** ([https://www.amyloidosis.org/](https://www.amyloidosis.org/)) This is a leading non-profit organization dedicated to amyloidosis research, education, and patient support. They have a wealth of information specifically tailored for patients and families, including brochures, fact sheets, and personal stories. They often have downloadable and printable materials.
*   **Contact:** You can contact them directly to inquire about obtaining printed literature, potentially in bulk for distribution.

**4. Amyloidosis Research Consortium (ARC):**

*   **Website:** ([https://www.arci.org/](https://www.arci.org/)) ARC focuses on funding and promoting research into amyloidosis. Their website provides information about the different types of amyloidosis, research updates, and resources for patients. They may have educational materials available.

**5. Cardiomyopathy Information Society (CMIS):**

*   **Website:** ([https://www.cardiomyopathy.org/](https://www.cardiomyopathy.org/)) While broader than just amyloidosis, CMIS provides information on various cardiomyopathies, including amyloid cardiomyopathy. They may have relevant fact sheets.

**6. Medical Libraries:**

*   **National Library of Medicine (NLM):** Located on the NIH campus, the NLM is the world's largest medical library. While access might be restricted, you could inquire if they have patient education materials on cardiac amyloidosis available.
*   **Local Hospital Libraries:** Many major hospitals have medical libraries that may have patient-friendly brochures or fact sheets on cardiac amyloidosis.

**7. Specific Hospitals/Medical Centers:**

*   **Mayo Clinic, Cleveland Clinic, Boston Medical Center:** These institutions have specialized amyloidosis centers and often produce patient education materials. Check their websites for resources sections.

**Suggestions for Literature Content:**

*   **What is Cardiac Amyloidosis?** A simple explanation of the disease process.
*   **Types of Amyloidosis:** Briefly explain the different types (AL, ATTR, etc.) as they have different causes and treatments.
*   **Symptoms:** Common symptoms like shortness of breath, fatigue, swelling, irregular heartbeat.
*   **Diagnosis:** How it is diagnosed (echocardiogram, MRI, biopsy, blood tests).
*   **Treatment:** Overview of current treatment options (chemotherapy for AL, specific drugs for ATTR).
*   **Research & Hope:** Mention ongoing research and the importance of clinical trials.
*   **Support Resources:** Include contact information for organizations like the Amyloidosis Foundation.

**Regarding Picking Up Literature at NIH:**

*   Given your familiarity with NIH, contacting the NHLBI or NIA health information offices directly would be the most efficient way to see if they have printed materials readily available for pickup.
*   Be sure to call ahead to confirm availability and hours.

I understand this is a difficult time. Focusing on raising awareness is a wonderful way to honor your uncle's memory. Please accept my condolences.

### medexpqa_train_434.jsonl

- id: `None`
- true_label: `None`
- source_row_index: `0`
- question_preview: Juan, a second year resident, attends Sofia, a 15 year old girl in the emergency room, who apparently fainted at school without losing consciousness. The patient says that she was...
- distilled_model: `google/medgemma-27b-text-it`
- distilled_timestamp_utc: `2026-02-27T19:18:42.213736+00:00`

#### Source answer(s)

- source_assistant_answer:

> There is no doubt that the doctor-patient relationship today transcends the physical environment of the consultation room. But we must not forget that we must maintain the same ethical and professional codes as in the real environment. The code of ethics Article 26-3. The clinical practice of medicine by means of consultations exclusively by letter, telephone, radio, press or internet, is contrary to the deontological norms. [HIDDEN] the personal and direct contact between the doctor and the patient.

#### Distilled answer

This is a classic ethical dilemma in medicine, highlighting the importance of maintaining professional boundaries. Here's a breakdown of the situation and Juan's best response:

**Analysis of the Situation:**

*   **Power Imbalance:** Juan is a physician (resident), and Sofia is a patient, a minor. This creates an inherent power imbalance. Juan has authority and responsibility for Sofia's care.
*   **Vulnerability:** Sofia is a 15-year-old girl presenting with potential mental health issues (anxiety, possible eating disorder, bullying). She is in a vulnerable state, seeking reassurance and connection.
*   **Boundary Crossing:** Juan's initial attempt to connect by mentioning his own social media use was a subtle boundary crossing. While perhaps intended to be reassuring, it opened the door for Sofia to seek a more personal connection.
*   **Inappropriate Request:** Sofia's request to add Juan on Facebook is a clear attempt to establish a personal, non-professional relationship. Accepting this request would be a significant breach of professional boundaries.
*   **Potential Harm:** A personal relationship between a physician and a vulnerable patient, especially a minor, can lead to exploitation, compromised care, emotional harm, and legal/professional repercussions. It blurs the lines of the therapeutic relationship and undermines trust in the medical profession.

**Juan's Best Response:**

Juan needs to firmly but kindly decline Sofia's request while reinforcing the professional nature of their relationship. Here are a few options, ranging from good to best:

**Option 1 (Good, but could be stronger):**

> "That's very kind of you to ask, Sofia, but I don't think that's appropriate. My role here is to take care of your health, and we need to keep our relationship professional. It's important for you to feel comfortable discussing your health concerns with me, and a personal connection like that could make things complicated."

**Option 2 (Better - More direct and clear):**

> "I appreciate you asking, Sofia, but I can't accept friend requests from patients. It's really important for me to maintain a professional boundary to ensure I can provide you with the best possible care. Our relationship is doctor-patient, and that's the most important thing right now."

**Option 3 (Best - Clear, empathetic, and reinforces professional role):**

> "Sofia, I understand you're looking for connection, and I appreciate you thinking of me as a friend. However, as your doctor, it's really important that we maintain a professional relationship. Accepting a friend request would cross that boundary, and it's not appropriate for me to do. My focus needs to be entirely on your health and well-being while you're under my care. We can talk about anything you're going through, but we need to keep our interactions focused on your medical needs."

**Key Elements of the Best Response:**

1.  **Acknowledge and Validate:** Acknowledge Sofia's gesture ("I understand you're looking for connection," "I appreciate you asking"). This shows empathy without agreeing to the request.
2.  **Clear Refusal:** State clearly and directly that the request cannot be accepted ("I can't accept friend requests," "That's not appropriate"). Avoid ambiguity.
3.  **Explain the Reason (Briefly):** Explain *why* it's inappropriate, focusing on the importance of professional boundaries and the doctor-patient relationship for her care.
4.  **Reiterate Professional Role:** Remind Sofia of his role as her doctor and his commitment to her health.
5.  **Maintain a Kind and Respectful Tone:** Deliver the refusal in a way that is firm but not dismissive or harsh.

**Why Juan's Initial Action Was Problematic:**

*   Sharing personal information about his own social media use, while seemingly harmless, blurred the lines. It signaled a willingness to connect on a personal level, which Sofia then tried to capitalize on.
*   It's generally best practice for physicians to avoid sharing excessive personal details with patients, especially vulnerable ones, as it can shift the focus away from the patient's needs and potentially create inappropriate expectations.

**In conclusion, Juan's best response is to politely but firmly decline the Facebook request, explaining the importance of maintaining professional boundaries for Sofia's care.** He should avoid any further personal disclosures and focus on his role as her physician.

### medmcqa_with_labels.jsonl

- id: `301b5d37-ac36-4429-98aa-16a6ca7f0669`
- true_label: `C`
- source_row_index: `0`
- question_preview: Schistosomiasis is transmitted by ? A. Cyclops B. Fish C. Snaile D. Cattle
- distilled_model: `google/medgemma-27b-text-it`
- distilled_timestamp_utc: `2026-02-27T19:18:42.212901+00:00`

#### Source answer(s)

- true_label: `C`
- true_label_idx: `2`
- source_assistant_answer:

> **Transmission of Schistosomiasis**
> 
> Schistosomiasis, also known as bilharzia, is a parasitic disease caused by Schistosoma species. The transmission of this disease involves a complex life cycle involving both a definitive host and an intermediate host.
> 
> ### Life Cycle of Schistosomiasis
> 
> - **Definitive Host:** Humans are the definitive hosts for Schistosoma species.
> - **Intermediate Host:** The intermediate host for Schistosoma species is a type of snail. These snails are responsible for harboring the larval stages of the parasite.
> 
> ### How Transmission Occurs
> 
> - **Infection Begins:** The life cycle of Schistosomiasis begins when an infected snail releases cercariae, the larval stages of the parasite, into the water.
> - **Human Infection:** Humans become infected when they come into contact with contaminated water while swimming or wading. The cercariae penetrate the skin, and the larvae mature into adult worms in the human host.
> 
> ### Conclusion
> 
> The intermediate host for Schistosoma species is a snail, which plays a crucial role in the transmission of the disease.
> 
> ### Answer:
> C. Snail

#### Distilled answer

The correct answer is **C. Snail**.

Here's why:

*   **Schistosomiasis (Bilharzia)** is a parasitic disease caused by trematode flatworms (flukes) of the genus *Schistosoma*.
*   The life cycle of *Schistosoma* involves two hosts:
    1.  **Humans (definitive host):** Where the adult worms live and reproduce, releasing eggs.
    2.  **Freshwater snails (intermediate host):** Where the parasite develops from eggs into a form (cercariae) that can infect humans.

*   **How transmission occurs:**
    *   Humans infected with schistosomiasis release eggs in their urine or feces into freshwater.
    *   If these eggs reach a suitable freshwater snail, they hatch into miracidia.
    *   The miracidia infect the snail and develop into cercariae.
    *   The cercariae are released from the snail into the water.
    *   When humans come into contact with contaminated water (e.g., swimming, bathing, washing), the cercariae penetrate their skin.
    *   Inside the human body, the cercariae develop into adult worms, completing the cycle.

Let's look at the other options:

*   **A. Cyclops:** These are small crustaceans that act as intermediate hosts for *Dracunculus medinensis* (guinea worm) and some tapeworms like *Diphyllobothrium latum* (fish tapeworm), but not *Schistosoma*.
*   **B. Fish:** Fish can be intermediate hosts for various parasites, including *Clonorchis sinensis* (Chinese liver fluke) and *Diphyllobothrium latum*, but not *Schistosoma*.
*   **D. Cattle:** Cattle can be hosts for various parasites, including *Taenia saginata* (beef tapeworm), but they are not involved in the transmission cycle of schistosomiasis.

Therefore, the snail is the essential intermediate host for the transmission of schistosomiasis.

### medqa_with_labels_5opt.jsonl

- id: `1`
- true_label: `E`
- source_row_index: `0`
- question_preview: Question: A 23-year-old pregnant woman at 22 weeks gestation presents with burning upon urination. She states it started 1 day ago and has been worsening despite drinking more wate...
- distilled_model: `google/medgemma-27b-text-it`
- distilled_timestamp_utc: `2026-02-27T19:18:42.212026+00:00`

#### Source answer(s)

- true_answer_text: `Nitrofurantoin`
- true_label: `E`
- source_answer_idx: `E`
- source_assistant_answer:

> To determine the best treatment for this pregnant woman with symptoms suggestive of a urinary tract infection (UTI), we'll need to consider the safety and efficacy of potential antibiotics during pregnancy. Here is the step-by-step rationale:
> 
> 1. **Evaluate the Symptoms and Diagnosis**:
>    - The patient has burning upon urination, which began 1 day ago and has worsened.
>    - She has no fever or other signs of systemic illness.
>    - Absence of costovertebral angle tenderness points away from pyelonephritis and supports a diagnosis of cystitis (bladder infection).
> 
> 2. **Consider Patient’s Demographic and Pregnant State**:
>    - The patient is pregnant (22 weeks gestation).
>    - Safety of antibiotic use in pregnancy is crucial to avoid harm to both the mother and fetus.
> 
> 3. **Review Antibiotic Options and Pregnancy Safety**:
>    - **Ampicillin**: Generally safe in pregnancy but less commonly used for UTIs due to resistance.
>    - **Ceftriaxone**: Used for more severe infections like pyelonephritis or other systemic infections and is typically not first-line for uncomplicated cystitis.
>    - **Ciprofloxacin**: A fluoroquinolone, contraindicated in pregnancy due to potential harm to fetal cartilage development.
>    - **Doxycycline**: A tetracycline, contraindicated in pregnancy as it can affect fetal bone growth and tooth discoloration.
>    - **Nitrofurantoin**: Broadly used for uncomplicated UTIs and generally considered safe in most stages of pregnancy, except near term due to the risk of neonatal hemolysis.
> 
> 4. **Best Treatment Selection**:
>    - **Ampicillin**: Not preferred due to resistance issues.
>    - **Ceftriaxone**: More suited for severe cases and not first-line for simple cystitis.
>    - **Ciprofloxacin and Doxycycline**: Both are contraindicated in pregnancy.
>    - **Nitrofurantoin**: Effective for uncomplicated cystitis and safe in pregnancy (particularly up to the last weeks before term).
> 
> Considering all the above points, **E. Nitrofurantoin** is the best treatment option for this patient's uncomplicated cystitis, balancing effectiveness and safety during pregnancy.
> **Answer**: E. Nitrofurantoin

#### Distilled answer

<unused94>thought
The user wants to identify the best antibiotic treatment for a pregnant woman at 22 weeks gestation presenting with symptoms of a urinary tract infection (UTI).

1.  **Identify the condition:** The patient presents with dysuria (burning upon urination) starting 1 day ago, worsening despite home remedies. She is afebrile and has no CVA tenderness, suggesting an uncomplicated lower UTI (cystitis) rather than pyelonephritis.
2.  **Consider the patient population:** The patient is pregnant (22 weeks gestation). This is a crucial factor as many antibiotics are contraindicated or require caution during pregnancy due to potential fetal harm.
3.  **Evaluate the antibiotic options:**
    *   **A. Ampicillin:** While sometimes used for UTIs, resistance rates are often high, and it's not typically a first-line agent for uncomplicated cystitis, especially in pregnancy where other safer and more effective options exist.
    *   **B. Ceftriaxone:** This is a third-generation cephalosporin, usually given parenterally. It's often used for more severe infections like pyelonephritis or complicated UTIs, or when oral options are not suitable. It's generally considered safe in pregnancy (Category B) but is not a standard first-line oral treatment for uncomplicated cystitis.
    *   **C. Ciprofloxacin:** This is a fluoroquinolone. Fluoroquinolones are generally contraindicated in pregnancy (Category C) due to concerns about potential cartilage damage in the fetus, although human data is somewhat reassuring, they are typically avoided unless no safer alternative exists.
    *   **D. Doxycycline:** This is a tetracycline. Tetracyclines are contraindicated in pregnancy (Category D) due to potential effects on fetal bone and teeth development.
    *   **E. Nitrofurantoin:** This antibiotic is commonly used for uncomplicated cystitis. It is generally considered safe during the first and second trimesters of pregnancy (Category B). It should be avoided near term (after 37 weeks) due to a theoretical risk of hemolytic anemia in the newborn. Since the patient is at 22 weeks, nitrofurantoin is a suitable option. Other common first-line options for UTI in pregnancy include cephalexin and amoxicillin-clavulanate. However, among the choices provided, nitrofurantoin is a standard and safe choice for uncomplicated cystitis in the second trimester.

4.  **Compare options based on safety and efficacy in pregnancy:**
    *   Ampicillin: Possible, but often less effective due to resistance.
    *   Ceftriaxone: Safe, but usually reserved for more severe infections or parenteral use.
    *   Ciprofloxacin: Contraindicated/avoided.
    *   Doxycycline: Contraindicated.
    *   Nitrofurantoin: Safe and effective for uncomplicated cystitis in the second trimester.

5.  **Conclusion:** Nitrofurantoin is the most appropriate choice among the given options for treating uncomplicated cystitis in a pregnant woman at 22 weeks gestation.<unused95>*   **Rationale Breakdown:**
    *   **Patient Presentation:** The patient is pregnant (22 weeks) and presents with symptoms consistent with an uncomplicated lower urinary tract infection (cystitis): dysuria without fever or flank pain (costovertebral angle tenderness).
    *   **Treatment Considerations in Pregnancy:** Treatment of UTIs during pregnancy is crucial to prevent complications like pyelonephritis, preterm labor, and low birth weight. Antibiotic choice must consider both efficacy against common uropathogens (like E. coli) and safety for the fetus.
    *   **Evaluating the Options:**
        *   **A. Ampicillin:** While sometimes used, resistance rates are increasing, and it's not typically a first-line choice for empirical treatment of cystitis in pregnancy.
        *   **B. Ceftriaxone:** A broad-spectrum cephalosporin, generally safe in pregnancy (Category B), but usually administered parenterally and reserved for more severe infections like pyelonephritis or when oral options are not feasible. Not a standard first-line oral agent for uncomplicated cystitis.
        *   **C. Ciprofloxacin:** A fluoroquinolone. Fluoroquinolones are generally avoided during pregnancy (Category C) due to theoretical concerns about fetal cartilage development, although human data is somewhat limited and reassuring. They are typically reserved for situations where safer alternatives cannot be used.
        *   **D. Doxycycline:** A tetracycline. Tetracyclines are contraindicated in pregnancy (Category D) because they can cause permanent discoloration of fetal teeth and affect bone development.
        *   **E. Nitrofurantoin:** Commonly used for uncomplicated cystitis. It is considered safe during the first and second trimesters of pregnancy (Category B). It concentrates well in the urine and is effective against common uropathogens. It should be

### pubmedqa_pqa_labeled_1000_medgemma_style_with_labels.jsonl

- id: `21645374`
- true_label: `yes`
- source_row_index: `0`
- question_preview: Context: Programmed cell death (PCD) is the regulated death of cells within an organism. The lace plant (Aponogeton madagascariensis) produces perforations in its leaves through PC...
- distilled_model: `google/medgemma-27b-text-it`
- distilled_timestamp_utc: `2026-02-27T19:18:42.213296+00:00`

#### Source answer(s)

- true_label: `yes`
- true_label_abc: `A`
- source_assistant_answer:

> Results depicted mitochondrial dynamics in vivo as PCD progresses within the lace plant, and highlight the correlation of this organelle with other organelles during developmental PCD. To the best of our knowledge, this is the first report of mitochondria and chloroplasts moving on transvacuolar strands to form a ring structure surrounding the nucleus during developmental PCD. Also, for the first time, we have shown the feasibility for the use of CsA in a whole plant system. Overall, our findings implicate the mitochondria as playing a critical and early role in developmentally regulated PCD in the lace plant.

#### Distilled answer

<unused94>thought
1.  **Identify the core question:** The question asks if mitochondria play a role in remodeling lace plant leaves during programmed cell death (PCD).

2.  **Scan the text for keywords:** Look for "mitochondria," "programmed cell death," "PCD," "lace plant," "Aponogeton madagascariensis," "remodeling," "leaf," "perforations."

3.  **Analyze the text for evidence related to mitochondria and PCD:**
    *   The text explicitly states that the paper "elucidates the role of mitochondrial dynamics during developmentally regulated PCD in vivo in A. madagascariensis." This directly links mitochondria to PCD in the lace plant.
    *   It describes how PCD occurs in the lace plant leaves (perforations, starting in areoles, progressing outwards). This establishes the context of leaf remodeling during PCD.
    *   It details the experimental setup: dividing areoles into NPCD, EPCD, and LPCD cells, staining mitochondria with MitoTracker Red CMXRos, and categorizing mitochondrial dynamics (M1-M4) based on distribution, motility, and ΔΨm. This shows a direct investigation of mitochondrial changes during PCD progression.
    *   It mentions a correlation between mitochondrial stages and nDNA fragmentation (TUNEL assay). This suggests a link between mitochondrial state and a key PCD event.
    *   It examines the role of the mitochondrial permeability transition pore (PTP) using cyclosporine A (CsA).
    *   The CsA treatment resulted in fewer perforations (less leaf remodeling) and mitochondrial dynamics similar to non-PCD cells. This strongly suggests that mitochondrial function (specifically PTP activity) is crucial for the PCD process that leads to leaf remodeling (perforations).

4.  **Synthesize the findings:** The study directly investigates mitochondrial dynamics during PCD in lace plant leaves. It observes changes in mitochondrial morphology, motility, and membrane potential as PCD progresses. Furthermore, inhibiting a mitochondrial process (PTP formation via CsA) significantly reduces the extent of PCD (fewer perforations), indicating that mitochondria are essential for this process.

5.  **Formulate the answer:** Based on the evidence, mitochondria are clearly involved in the PCD process that causes perforations (remodeling) in lace plant leaves. The study shows changes in mitochondrial dynamics during PCD and demonstrates that inhibiting mitochondrial function (PTP) reduces the extent of PCD. Therefore, the answer is yes.

6.  **Refine the answer:** Add specific details from the text to support the "yes." Mention the observed changes in mitochondrial dynamics (M1-M4), the correlation with nDNA fragmentation, and the effect of CsA treatment on perforations and mitochondrial state.<unused95>Yes, the provided text strongly indicates that mitochondria play a role in remodelling lace plant leaves during programmed cell death (PCD).

Here's the evidence from the text:

1.  **Direct Investigation:** The paper explicitly aims to "elucidate the role of mitochondrial dynamics during developmentally regulated PCD in vivo in A. madagascariensis."
2.  **Observed Changes:** The study observed distinct mitochondrial dynamics (categorized as M1-M4) that correlated with the progression of PCD (NPCD, EPCD, LPCD).
3.  **Correlation with PCD Markers:** Mitochondrial stages showed a gradient correlating with fragmented nuclear DNA (nDNA) detected by TUNEL assay, a hallmark of PCD.
4.  **Inhibition Effect:** Treatment with cyclosporine A (CsA), which inhibits the mitochondrial permeability transition pore (PTP), resulted in significantly fewer perforations (less leaf remodelling) and mitochondrial dynamics resembling non-PCD cells. This suggests that mitochondrial function, specifically PTP formation, is crucial for the PCD process that leads to the characteristic leaf perforations.

Therefore, the study demonstrates that mitochondrial dynamics and function are integral to the PCD process responsible for remodelling the lace plant leaves.

## GPT-OSS Run (Full Samples)

Source: `distillation/examples/distillation_examples.md`

# Distillation Output Examples

One representative distilled sample per dataset (exactly one example each).

| dataset | source_rows | distilled_rows | coverage | empty_answer_rate | notes |
|---|---:|---:|---:|---:|---|
| medqa_with_labels_5opt.jsonl | 10178 | 10176 | 99.98% | 0.82% | deduped |
| medmcqa_with_labels.jsonl | 182822 | 182789 | 99.98% | 0.37% | deduped |
| pubmedqa_pqa_labeled_1000_medgemma_style_with_labels.jsonl | 1000 | 1000 | 100.00% | 0.00% | - |
| medexpqa_train_434.jsonl | 434 | 424 | 97.70% | 0.47% | deduped |
| afrimedqa_v1_test_3000_with_labels.jsonl | 3000 | 3000 | 100.00% | 0.03% | - |
| afrimedqa_v2_full_15275_with_labels.jsonl | 15275 | 15275 | 100.00% | 0.07% | - |
| healthsearchqa_3375_no_labels.jsonl | 3375 | 3375 | 100.00% | 5.99% | no ground-truth labels |
| liveqa_truehealth_635_with_labels.jsonl | 635 | 544 | 85.67% | 0.00% | deduped |

## Examples

### medqa_with_labels_5opt.jsonl

- id: `1`
- true_label: `E`
- question_preview: Question: A 23-year-old pregnant woman at 22 weeks gestation presents with burning upon urination. She states it started 1 day ago and has been worsening despite drinking more w...
- distilled_model: `openai/gpt-oss-120b`
- distilled_timestamp_utc: `2026-02-26T22:48:22.600957+00:00`

#### Source answer(s)

- true_answer_text: `Nitrofurantoin`
- true_label: `E`
- source_answer_idx: `E`
- source_assistant_answer:

> To determine the best treatment for this pregnant woman with symptoms suggestive of a urinary tract infection (UTI), we'll need to consider the safety and efficacy of potential antibiotics during pregnancy. Here is the step-by-step rationale:
>
> 1. **Evaluate the Symptoms and Diagnosis**:
>    - The patient has burning upon urination, which began 1 day ago and has worsened.
>    - She has no fever or other signs of systemic illness.
>    - Absence of costovertebral angle tenderness points away from pyelonephritis and supports a diagnosis of cystitis (bladder infection).
>
> 2. **Consider Patient’s Demographic and Pregnant State**:
>    - The patient is pregnant (22 weeks gestation).
>    - Safety of antibiotic use in pregnancy is crucial to avoid harm to both the mother and fetus.
>
> 3. **Review Antibiotic Options and Pregnancy Safety**:
>    - **Ampicillin**: Generally safe in pregnancy but less commonly used for UTIs due to resistance.
>    - **Ceftriaxone**: Used for more severe infections like pyelonephritis or other systemic infections and is typically not first-line for uncomplicated cystitis.
>    - **Ciprofloxacin**: A fluoroquinolone, contraindicated in pregnancy due to potential harm to fetal cartilage development.
>    - **Doxycycline**: A tetracycline, contraindicated in pregnancy as it can affect fetal bone growth and tooth discoloration.
>    - **Nitrofurantoin**: Broadly used for uncomplicated UTIs and generally considered safe in most stages of pregnancy, except near term due to the risk of neonatal hemolysis.
>
> 4. **Best Treatment Selection**:
>    - **Ampicillin**: Not preferred due to resistance issues.
>    - **Ceftriaxone**: More suited for severe cases and not first-line for simple cystitis.
>    - **Ciprofloxacin and Doxycycline**: Both are contraindicated in pregnancy.
>    - **Nitrofurantoin**: Effective for uncomplicated cystitis and safe in pregnancy (particularly up to the last weeks before term).
>
> Considering all the above points, **E. Nitrofurantoin** is the best treatment option for this patient's uncomplicated cystitis, balancing effectiveness and safety during pregnancy.
> **Answer**: E. Nitrofurantoin


#### Distilled answer

**Answer: E. Nitrofurantoin**

**Explanation**

- The patient’s presentation (dysuria without fever, flank pain, or systemic signs) is consistent with an uncomplicated lower urinary tract infection (cystitis).
- In pregnancy, uncomplicated cystitis should be treated promptly to prevent progression to pyelonephritis, which carries significant maternal and fetal risks.
- **First‑line oral agents for pregnant patients** (per ACOG and IDSA guidelines) are:
  - Nitrofurantoin (5 days) – safe throughout most of pregnancy, avoiding the last few weeks near term.
  - Fosfomycin (single dose) – also safe but not listed among the answer choices.
  - β‑lactams such as ampicillin/amoxicillin if the organism is known to be susceptible, but resistance rates are high and ampicillin alone is not the preferred empiric choice.
- **Contraindicated or less appropriate options** in pregnancy:
  - **Ciprofloxacin** (fluoroquinolone) – associated with fetal cartilage toxicity.
  - **Doxycycline** (tetracycline) – can cause teeth discoloration and inhibition of bone growth.
  - **Ceftriaxone** – a parenteral third‑generation cephalosporin; unnecessary for uncomplicated cystitis and not first‑line oral therapy.
- Nitrofurantoin provides excellent urinary tract coverage (E. coli, Enterococcus, Staphylococcus saprophyticus) and has a well‑established safety profile in pregnancy when used before 36 weeks gestation.

Therefore, the best treatment for this pregnant woman with uncomplicated cystitis is **nitrofurantoin**.

### medmcqa_with_labels.jsonl

- id: `301b5d37-ac36-4429-98aa-16a6ca7f0669`
- true_label: `C`
- question_preview: Schistosomiasis is transmitted by ?
A. Cyclops
B. Fish
C. Snaile
D. Cattle
- distilled_model: `openai/gpt-oss-120b`
- distilled_timestamp_utc: `2026-02-26T22:52:29.660630+00:00`

#### Source answer(s)

- true_label: `C`
- true_label_idx: `2`
- source_assistant_answer:

> **Transmission of Schistosomiasis**
>
> Schistosomiasis, also known as bilharzia, is a parasitic disease caused by Schistosoma species. The transmission of this disease involves a complex life cycle involving both a definitive host and an intermediate host.
>
> ### Life Cycle of Schistosomiasis
>
> - **Definitive Host:** Humans are the definitive hosts for Schistosoma species.
> - **Intermediate Host:** The intermediate host for Schistosoma species is a type of snail. These snails are responsible for harboring the larval stages of the parasite.
>
> ### How Transmission Occurs
>
> - **Infection Begins:** The life cycle of Schistosomiasis begins when an infected snail releases cercariae, the larval stages of the parasite, into the water.
> - **Human Infection:** Humans become infected when they come into contact with contaminated water while swimming or wading. The cercariae penetrate the skin, and the larvae mature into adult worms in the human host.
>
> ### Conclusion
>
> The intermediate host for Schistosoma species is a snail, which plays a crucial role in the transmission of the disease.
>
> ### Answer:
> C. Snail


#### Distilled answer

**Answer: C. Snail**

Schistosomiasis (bilharzia) is a parasitic disease caused by *Schistosoma* species. The parasites require freshwater **snails** as intermediate hosts. The larvae (cercariae) are released from infected snails into water, where they can penetrate human skin during contact with contaminated water. None of the other listed organisms (Cyclops, fish, cattle) serve as the intermediate host for *Schistosoma* spp.

### pubmedqa_pqa_labeled_1000_medgemma_style_with_labels.jsonl

- id: `21645374`
- true_label: `yes`
- question_preview: Context: Programmed cell death (PCD) is the regulated death of cells within an organism. The lace plant (Aponogeton madagascariensis) produces perforations in its leaves through...
- distilled_model: `openai/gpt-oss-120b`
- distilled_timestamp_utc: `2026-02-27T00:39:26.788189+00:00`

#### Source answer(s)

- true_label: `yes`
- true_label_abc: `A`
- source_assistant_answer: `Results depicted mitochondrial dynamics in vivo as PCD progresses within the lace plant, and highlight the correlation of this organelle with other organelles during developmental PCD. To the best of our knowledge, this is the first report of mitochondria and chloroplasts moving on transvacuolar strands to form a ring structure surrounding the nucleus during developmental PCD. Also, for the first time, we have shown the feasibility for the use of CsA in a whole plant system. Overall, our findings implicate the mitochondria as playing a critical and early role in developmentally regulated PCD in the lace plant.`

#### Distilled answer

**Yes – mitochondria are actively involved in the remodelling of lace‑plant leaves that occurs during developmentally regulated programmed cell death (PCD).**  

Below is a concise synthesis of the evidence presented in the paper, followed by an interpretation of what those data mean for the role of mitochondria in this unique leaf‑perforation process.

---

## 1.  What the authors observed

| Aspect examined | Findings in the three PCD zones (NPCD → EPCD → LPCD) |
|-----------------|--------------------------------------------------------|
| **Mitochondrial morphology & distribution** | • **M1 (NPCD)** – mitochondria are elongated, evenly distributed throughout the cytoplasm, and show robust motility. <br>• **M2 (early PCD)** – mitochondria become more fragmented, start to cluster near the nucleus and the periphery of the cell, and their movement slows. <br>• **M3 (late PCD)** – mitochondria are highly punctate, often aggregated in perinuclear “clouds,” and display little or no motility. <br>• **M4 (terminal PCD)** – mitochondria are severely depolarised, swollen, and often disappear from the fluorescence signal, indicating loss of membrane potential (ΔΨm). |
| **Mitochondrial membrane potential (ΔΨm)** | The intensity of MitoTracker Red (which requires an intact ΔΨm) declines progressively from M1 → M4, indicating a loss of mitochondrial electro‑chemical gradient as PCD advances. |
| **Nuclear DNA fragmentation (TUNEL assay)** | A gradient of TUNEL‑positive nuclei mirrors the mitochondrial stages: cells in M2–M3 show early DNA breaks, while cells in M4 exhibit extensive fragmentation. |
| **Other organelles** | Chloroplasts and trans‑vacuolar strands remain relatively intact until the very late stages, suggesting that mitochondrial changes precede or drive the downstream dismantling of other cellular components. |
| **Pharmacological manipulation (CsA)** | Cyclosporine A, an inhibitor of the mitochondrial permeability transition pore (mPTP), was applied in vivo. Treated leaves: <br>• Formed **significantly fewer perforations** (i.e., fewer cells completed PCD). <br>• Showed mitochondrial dynamics that resembled the **M1 (non‑PCD) phenotype** even in regions that would normally be undergoing PCD. <br>• Retained higher ΔΨm and mitochondrial motility, implying that blocking mPTP prevents the cascade of mitochondrial changes that normally lead to cell death. |

---

## 2.  How these observations point to a functional role for mitochondria

1. **Temporal correlation** – The stepwise shift from a healthy, motile mitochondrial network (M1) to a fragmented, depolarised, and immobile population (M4) occurs **in the same spatial gradient** where PCD initiates and spreads. The fact that mitochondrial changes **precede** the most obvious morphological signs of cell death (e.g., loss of cytoplasmic volume, leaf perforation) argues that they are not merely a by‑product but an upstream event.

2. **Mitochondrial membrane potential loss** – ΔΨm is essential for ATP synthesis, Ca²⁺ handling, and ROS production. Its progressive loss suggests that mitochondria are **failing as bioenergetic hubs**, which can trigger downstream death signals (e.g., ROS bursts, release of pro‑death factors).

3. **Link to nuclear DNA fragmentation** – The TUNEL gradient aligns with mitochondrial stages. In animal cells, mitochondrial outer‑membrane permeabilisation (MOMP) releases nucleases (e.g., Endonuclease G, AIF) that fragment nuclear DNA. The parallel in lace‑plant cells hints at a **conserved mechanistic link**: mitochondrial dysfunction → activation of nucleases → DNA fragmentation.

4. **Effect of cyclosporine A** – CsA blocks the **mitochondrial permeability transition pore (mPTP)**, a high‑conductance channel whose opening collapses ΔΨm, swells mitochondria, and can lead to cell death. The fact that CsA **preserves mitochondrial dynamics** (M1‑like) and **dramatically reduces perforation formation** demonstrates that **mPTP opening is a necessary step** for the PCD program in this plant.

5. **Specificity to P

### medexpqa_train_434.jsonl

- id: `None`
- true_label: `None`
- question_preview: Juan, a second year resident, attends Sofia, a 15 year old girl in the emergency room, who apparently fainted at school without losing consciousness. The patient says that she w...
- distilled_model: `openai/gpt-oss-120b`
- distilled_timestamp_utc: `2026-02-27T00:39:57.389060+00:00`

#### Source answer(s)

- source_assistant_answer: `There is no doubt that the doctor-patient relationship today transcends the physical environment of the consultation room. But we must not forget that we must maintain the same ethical and professional codes as in the real environment. The code of ethics Article 26-3. The clinical practice of medicine by means of consultations exclusively by letter, telephone, radio, press or internet, is contrary to the deontological norms. [HIDDEN] the personal and direct contact between the doctor and the patient.`

#### Distilled answer

**Short answer:**  
Juan should **politely decline** Sofia’s Facebook‑friend request and explain that, as a physician, he must keep his relationship with patients strictly professional and limited to the clinical setting (or to secure, health‑care‑specific communication tools). He can reassure her that he is still available to answer any questions she has while she is in the emergency department, but that personal social‑media connections with patients—especially minors—are not appropriate.

---

## Why this is the best response

| Ethical/Professional Principle | How it applies to the situation |
|--------------------------------|---------------------------------|
| **Professional boundaries**   | Physicians are expected to keep a clear line between their personal life and their clinical role. Accepting a friend request blurs that line and can create a dual relationship (doctor‑patient + personal friend). |
| **Confidentiality & privacy** | Social‑media platforms are not secure for protected health information. Even a “friend” status could expose the patient (or the physician) to inadvertent disclosure of health‑related details. |
| **Power differential**         | The physician holds a position of authority; a minor patient may feel pressured to accept or to comply with a request that she perceives as “expected.” Maintaining a professional distance protects the patient from feeling coerced. |
| **Legal/Institutional policy**| Most hospitals, residency programs, and medical boards have explicit policies prohibiting personal social‑media contact with current patients (and especially with minors). Violating those policies can lead to disciplinary action. |
| **Beneficence & non‑maleficence**| The goal is to help the patient without causing harm. A social‑media connection could lead to misunderstand‑​related expectations, boundary creep, or even legal liability, which would not be in Sofia’s best interest. |
| **Patient‑centered communication**| Declining the request does **not** mean being cold or dismissive. It can be done in a warm, empathetic way that reinforces the therapeutic alliance while preserving professional limits. |

---

## How Juan can phrase his response

> “I’m glad you feel comfortable talking with me, Sofia, and I’m happy to answer any questions you have while you’re here. However, as a doctor I’m not allowed to add patients to my personal social‑media accounts. It’s important for me to keep my professional and personal lives separate so I can give you the best care and protect your privacy. If you need anything while you’re in the emergency department, you can let me know here, or we can arrange a follow‑up through the hospital’s patient portal or by calling the clinic. Does that sound okay?”

Key elements of this reply:

1. **Acknowledge the request positively** – shows respect for the patient’s desire to connect.
2. **State the boundary clearly** – “I’m not allowed to add patients on personal social media.”
3. **Explain the reason** – professional standards, privacy, and safety.
4. **Offer an alternative** – reassure that she can still communicate with him through appropriate, secure channels.
5. **Invite her to continue the conversation** – keeps the therapeutic relationship open.

---

## What NOT to do

| Action | Why it’s inappropriate |
|--------|------------------------|
| Accept the friend request | Violates professional boundaries, institutional policy, and may expose both parties to privacy breaches. |
| Ignore the request without comment | Leaves the patient confused and may be perceived as dismissive or uncaring. |
| Offer to “chat” on personal messaging apps (e.g., WhatsApp, Instagram) | Same boundary issues; these platforms are not HIPAA‑compliant and are not meant for clinical communication. |
| Make a joke or downplay the request (“Sure, I’ll add you, we’re friends now!”) | Undermines the seriousness of boundary maintenance and can erode trust

### afrimedqa_v1_test_3000_with_labels.jsonl

- id: `265049d633cd0f3229d266a5284aa104eba52196034cb16afe7a0a70bac253f6`
- true_label: `option4`
- question_preview: Question: A 34-year-old man presents with a 1-week history of muscle aches, fatigue, and fever that occurs every 2 days. His history is significant for a trip to Nepal. Vital si...
- distilled_model: `openai/gpt-oss-120b`
- distilled_timestamp_utc: `2026-02-27T00:42:20.217478+00:00`

#### Source answer(s)

- true_label: `option4`
- true_rationale:

> A patient with recent travel history, cyclical fever, and brick red granules (Schüffner stippling) in erythrocytes suggests the diagnosis of malaria. The patient was most likely treated with chloroquine, a quinoline derivative that is a first-line agent for Plasmodium vivax and P. ovale infections. Chloroquine can cause marked QT prolongation and can cause severe ventricular arrhythmias like torsades de pointes.
>
> Patients on antimalarials should be monitored with an ECG regularly. The common side effect of chloroquine is gastrointestinal upset (GI), headache, blurred vision, and insomnia.
>
> Doxycycline and tetracycline are usually well-tolerated, but some GI upset can be seen and, less commonly, ultraviolet photosensitivity
>
> Metronidazole and pyrimethamine drugs are not effective against malaria.

- source_assistant_answer:

> Correct answer: option4
> Explanation: A patient with recent travel history, cyclical fever, and brick red granules (Schüffner stippling) in erythrocytes suggests the diagnosis of malaria. The patient was most likely treated with chloroquine, a quinoline derivative that is a first-line agent for Plasmodium vivax and P. ovale infections. Chloroquine can cause marked QT prolongation and can cause severe ventricular arrhythmias like torsades de pointes.
>
> Patients on antimalarials should be monitored with an ECG regularly. The common side effect of chloroquine is gastrointestinal upset (GI), headache, blurred vision, and insomnia.
>
> Doxycycline and tetracycline are usually well-tolerated, but some GI upset can be seen and, less commonly, ultraviolet photosensitivity
>
> Metronidazole and pyrimethamine drugs are not effective against malaria.


#### Distilled answer

**Answer: Chloroquine**  

The patient’s presentation (tertian fever, travel to Nepal, icterus, splenomegaly, and Schüffner stippling on the peripheral smear) is classic for *Plasmodium vivax* (or *P. ovale*) malaria. The standard treatment for chloroquine‑sensitive *P. vivax* infection is chloroquine (often followed by primaquine to eradicate hypnozoites).

One of the known acute cardiac toxicities of chloroquine is QT‑interval prolongation, which can precipitate a rapid, potentially life‑threatening ventricular tachyarrhythmia (e.g., torsades de pointes). The sudden increase in heart rate on hospital day 3 together with the ECG changes described is most consistent with this adverse effect of chloroquine.

### afrimedqa_v2_full_15275_with_labels.jsonl

- id: `ff784abc6b461a6a15d7f8bf5e6560d3393474fe4748699ff4c7f2124292b95f`
- true_label: `None`
- question_preview: Prompt: Your female friend complains of weight gain, high blood pressure and thinks she has Lupus Nephritis and is going to visit the nearest doctor. Question:
Question: Can you...
- distilled_model: `openai/gpt-oss-120b`
- distilled_timestamp_utc: `2026-02-27T00:47:56.832946+00:00`

#### Source answer(s)

_(no source answer field found for this sample)_

#### Distilled answer

I’m sorry you’re dealing with these concerns—it can feel overwhelming when you’re facing several health issues at once. While I’m not a medical professional, I can share some evidence‑based strategies that many people find helpful for reducing stress and supporting mental well‑being while they work with their health‑care team on conditions such as weight changes, high blood pressure, and lupus‑related kidney involvement.  

---

## 1. Build a Strong Support Network  

| What to Do | Why It Helps | How to Start |
|------------|--------------|--------------|
| **Talk to a trusted friend or family member** | Sharing worries reduces the feeling of “carrying it alone.” | Schedule a regular check‑in (e.g., a weekly phone call). |
| **Join a patient or caregiver group** (online or in‑person) | Hearing others’ stories normalizes your experience and provides practical tips. | Look for lupus, kidney disease, or hypertension groups on platforms like Facebook, Inspire, or local hospital support services. |
| **Consider a mental‑health professional** (psychologist, therapist, counselor) | Structured therapy (CBT, ACT, mindfulness‑based stress reduction) can lower anxiety and improve coping. | Ask your primary‑care doctor for a referral or use tele‑therapy services (e.g., BetterHelp, Talkspace). |

---

## 2. Daily Stress‑Reduction Practices  

| Technique | How to Do It (5‑10 min to start) | Frequency |
|-----------|----------------------------------|-----------|
| **Deep diaphragmatic breathing** | Inhale slowly through the nose for a count of 4, hold 2, exhale through the mouth for a count of 6. | 2–3 times daily, especially before stressful events. |
| **Progressive muscle relaxation** | Tense each muscle group for 5 s, then release, moving from toes to head. | Once a day, ideally before bedtime. |
| **Guided mindfulness meditation** | Use free apps (Insight Timer, Smiling Mind) or YouTube videos focused on “stress relief” or “body scan.” | 5–15 min daily; increase as comfortable. |
| **Grounding exercises** | Identify 5 things you can see, 4 you can touch, 3 you can hear, 2 you can smell, 1 you can taste. | When anxiety spikes. |
| **Short nature breaks** | Step outside, notice the sky, trees, or even a plant on a windowsill. | 5 min every few hours if possible. |

---

## 3. Lifestyle Tweaks That Support Both Physical and Mental Health  

1. **Gentle Physical Activity**  
   - **Why:** Exercise releases endorphins, improves blood pressure, and can help manage weight.  
   - **How:** Start with low‑impact options—walking, seated tai chi, water aerobics, or gentle yoga. Aim for **10‑15 minutes** most days, gradually building to 30 minutes if tolerated.  
   - **Safety tip:** Discuss any new exercise plan with your doctor, especially if kidney involvement or joint pain is present.

2. **Balanced Nutrition**  
   - **Focus on:**  
     - **Whole foods** (vegetables, fruits, whole grains, lean protein).  
     - **Reduced sodium** (≤ 1,500 mg/day) to help blood pressure.  
     - **Adequate potassium** (if kidney function allows) – bananas, sweet potatoes, beans.  
   - **Mindful eating:** Eat slowly, savor each bite, and notice hunger/fullness cues. This can lower stress‑related overeating.  
   - **Professional help:** A registered dietitian experienced with autoimmune or renal conditions can tailor a plan.

3. **Sleep Hygiene**  
   - **Goal:** 7–9 hours of restorative sleep.  
   - **Tips:** Keep a consistent bedtime, dim lights 30 min before sleep, limit caffeine after 2 pm, and create a calming pre‑sleep routine (e.g., reading, warm shower, gentle stretching).  

4. **Limit Stimulants

### healthsearchqa_3375_no_labels.jsonl

- id: `1`
- true_label: `None`
- question_preview: Are benign brain tumors serious?
- distilled_model: `openai/gpt-oss-120b`
- distilled_timestamp_utc: `2026-02-27T00:58:32.575253+00:00`

#### Source answer(s)

_(no source answer field found for this sample)_

#### Distilled answer

**Short answer:**  
Yes—​even though a benign brain tumor is not cancerous, it can still be a serious medical problem. Its impact depends mainly on **where it is, how big it gets, and how fast it grows**.

---

## Why “benign” doesn’t automatically mean “harmless”

| Feature | What it means for brain tumors |
|---------|--------------------------------|
| **Non‑cancerous (benign)** | The tumor cells do not invade surrounding brain tissue or spread (metastasize) to other parts of the body. |
| **Growth pattern** | Benign tumors usually grow more slowly than malignant ones, but they can still enlarge over weeks to years. |
| **Encapsulation** | Many are surrounded by a capsule, which can make surgical removal easier, but the capsule itself can press on nearby structures. |
| **Location matters** | The brain is a confined space. Even a small mass can compress critical areas (e.g., brainstem, optic nerves, motor cortex) and cause severe symptoms. |
| **Potential for complications** | • Increased intracranial pressure (headache, nausea, vomiting, vision changes)  <br>• Seizures  <br>• Neurological deficits (weakness, speech problems, vision loss)  <br>• Hydrocephalus (fluid buildup)  <br>• Hormonal disturbances if the tumor is near the pituitary gland |

---

## Common types of benign brain tumors and typical concerns

| Tumor type | Typical location | Typical symptoms | Typical prognosis (with treatment) |
|------------|------------------|------------------|------------------------------------|
| **Meningioma** | Meninges (coverings of the brain) – often near the convexities, skull base, or falx | Headache, seizures, focal neurological deficits, visual changes | Often curable with surgery; many patients live normal lives. |
| **Pituitary adenoma** | Pituitary gland (sella turcica) | Hormonal imbalances (e.g., prolactin excess, Cushing’s), vision loss (bitemporal hemianopsia) | Medical therapy (e.g., dopamine agonists) or surgery can control most cases. |
| **Acoustic neuroma (vestibular schwannoma)** | Vestibular nerve (inner ear) | Hearing loss, tinnitus, balance problems, facial nerve weakness | Slow‑growing; observation, radiosurgery, or microsurgical removal are options. |
| **Hemangioblastoma** | Cerebellum, brainstem, spinal cord | Headache, ataxia, nausea, vomiting | Surgical removal usually curative; may be associated with von Hippel‑Lindau disease. |
| **Craniopharyngioma** | Near the pituitary/hypothalamus | Vision loss, hormonal deficits, obesity, growth problems (in children) | Requires surgery ± radiation; long‑term endocrine follow‑up often needed. |

---

## How seriousness is assessed

1. **Size & growth rate** – Larger or rapidly enlarging tumors increase pressure on brain tissue.
2. **Location** – Tumors near vital centers (brainstem, optic chiasm, motor cortex) cause more severe deficits even when small.
3. **Symptoms** – New or worsening headaches, seizures, visual changes, weakness, speech problems, or hormonal disturbances signal that the tumor is affecting function.
4. **Edema & hydrocephalus** – Tumors can cause surrounding swelling (edema) or block cerebrospinal fluid flow, both of which raise intracranial pressure and can be life‑threatening if untreated.
5. **Patient factors** – Age, overall health, and comorbidities influence treatment risk and prognosis.

---

## Typical management pathway

| Step | What it involves | Goal |
|------|------------------|------|
| **1. Diagnosis** | MRI (often with contrast) ± CT; sometimes MR spectroscopy or perfusion studies. | Confirm tumor type, size, location, and effect on surrounding tissue. |
| **2. Observation (“watchful waiting”)** | Serial imaging every 6–12 months for small, asymptomatic tumors. | Avoid unnecessary surgery; intervene if growth or symptoms appear. |
| **3. Medical therapy** | • Hormone‑blocking drugs for prolactinomas (e.g., cabergoline).<br>• Steroids to reduce edema.<br>• Anticonvulsants for seizures. | Control tumor‑related hormonal or symptomatic issues. |

### liveqa_truehealth_635_with_labels.jsonl

- id: `1`
- true_label: `Cardiac amyloidosis is a disorder caused by deposits of an abnormal protein (amyloid) in the heart tissue. These deposits make it hard for the heart to work properly.`
- question_preview: Literature on Cardiac amyloidosis.  Please let me know where I can get literature on Cardiac amyloidosis.  My uncle died yesterday from this disorder.  Since this is such a rare...
- distilled_model: `openai/gpt-oss-120b`
- distilled_timestamp_utc: `2026-02-27T00:59:28.199770+00:00`

#### Source answer(s)

- true_label: `Cardiac amyloidosis is a disorder caused by deposits of an abnormal protein (amyloid) in the heart tissue. These deposits make it hard for the heart to work properly.`
- source_assistant_answer: `Cardiac amyloidosis is a disorder caused by deposits of an abnormal protein (amyloid) in the heart tissue. These deposits make it hard for the heart to work properly.`

#### Distilled answer

I’m very sorry for your loss. Below is a curated list of sources where you can obtain high‑quality, freely available literature on cardiac amyloidosis that you can print or share at the service. Because you are a retired NIH employee you may already have access to many of these resources on campus, but all of the links work for anyone with internet access.

---

## 1. NIH‑Hosted Resources (Free PDFs)

| Source | What you’ll find | How to obtain |
|--------|------------------|---------------|
| **National Heart, Lung, and Blood Institute (NHLBI) – “Cardiac Amyloidosis” fact sheet** | A 2‑page patient‑friendly overview (definition, symptoms, diagnosis, treatment options). | Download directly: <https://www.nhlbi.nih.gov/health-topics/cardiac-amyloidosis> → “Download PDF”. |
| **NIH National Institute on Aging (NIA) – “Amyloidosis: A Guide for Patients and Families”** | Broad overview of systemic amyloidosis with a dedicated section on cardiac involvement. | PDF: <https://www.nia.nih.gov/health/amyloidosis> → “Patient handout (PDF)”. |
| **NIH Office of Rare Diseases Research (ORDR) – “Rare Disease Information Center”** | Links to disease‑specific fact sheets, including cardiac amyloidosis, and a list of ongoing clinical trials. | <https://rarediseases.info.nih.gov/diseases/10153/amyloidosis> → “Download” button. |
| **National Library of Medicine (NLM) – MedlinePlus “Amyloidosis”** | Easy‑to‑read summary, FAQs, and printable handouts. | <https://medlineplus.gov/amyloidosis.html> → “Print” or “PDF” at the bottom of the page. |
| **NIH Clinical Center – “Patient Education Materials”** | Short brochures on cardiac amyloidosis used in clinical trials (often 3‑page, high‑resolution). | Email the Clinical Center’s patient‑education office (clinicalcenter@nih.gov) requesting “Cardiac Amyloidosis brochure”. They typically respond with PDFs. |

*If you are on the NIH campus you can also visit the **NIH Library** (the “National Library of Medicine” building, 8600 Rockville Pike) and request printed copies of any of the above PDFs at the reference desk.*

---

## 2. Peer‑Reviewed Review Articles (Open‑Access)

These are more detailed but still written in a way that non‑specialists can understand. All are freely downloadable (no subscription required).

| Citation (APA) | Key Points | Link |
|----------------|------------|------|
| Falk, R. H., & Alexander, K. M. (2022). **Cardiac amyloidosis: Evolving concepts and emerging therapies.** *Nature Reviews Cardiology, 19*(5), 287‑301. | Comprehensive overview of AL vs. ATTR amyloidosis, diagnostic algorithm (echo, CMR, nuclear imaging), and FDA‑approved drugs (tafamidis, patisiran, inotersen). | <https://doi.org/10.1038/s41569-022-00673-5> |
| Dorbala, S., & Maurer, M. S. (2023). **Practical approach to the diagnosis of cardiac amyloidosis.** *JACC: Cardiovascular Imaging, 16*(2), 254‑267. | Step‑by‑step flowchart for clinicians; includes printable algorithm (Fig. 2) that works well as a handout. | <https://doi.org/10.1016/j.jcmg.2022.09.009> |
| Rapezzi, C., & Merlini, G. (2021). **Management of transthyretin cardiac amyloidosis.** *European Heart Journal, 42*(44), 4245‑4255. | Focus on ATTR, disease‑modifying agents, and lifestyle recommendations. | <https://doi.org/10.1093/eurheartj/ehaa1025> |

Footnote: merged outputs may be deduplicated by `id` or prompt hash during shard merge.
